A Game Changer for Heart Disease Patients

South Tabor Medical Breakthrough News

“High levels of blood cholesterol, particularly low-density lipoproteins (LDL-C), are a significant contributor to cardiovascular disease.

In 2019, the FDA reviewed the application for inclisiran in treating primary hyperlipidemia (including hereditary hypercholesterolemia) in adults who have elevated LDL-C while on a maximally tolerated dose of statin therapy. Inclisiran is an injectable, chemically synthesized small interfering RNA that targets the PCSK9 protein.

In contrast to statins, it requires infrequent dosing (twice per year) and provides effective and sustained LDL-C reduction in conjunction with statins. Its prolonged effect may help alleviate medication noncompliance, one of the leading causes of failure to lower LDL-C levels. Inclisiran was approved by the FDA in December 2021 and is widely considered a game changer for heart disease patients.” [ Source Link ]

Before taking inclisiran follow the below guidelines:

  • “…. tell your doctor and pharmacist if you are allergic to inclisiran, any other medications, or any of the ingredients in inclisiran injection. Ask your pharmacist for a list of the ingredients.
  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take.
  • tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while taking inclisiran injection, call your doctor.”
  • [ Source Link]